Prevalence of Dio2T92A polymorphism and its association with thyroid autoimmunity

Journal of Endocrinological Investigation

Volumn 36, Issue 5, 2013, Pages 303-306

  Guerra, A ^a   Sapio, M R ^a   Carrano, M ^b   Di Stasi, V ^a   Volpe, A ^a   Murino, A ^a   Izzo, G ^a   Vitale, M ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY HOSPITAL SAN GIOVANNI DI DIO E RUGGI D ARAGONA   (Italy)

Author keywords

Dio2T92A polymorphism; Thyroid autoimmunity; Type 2 iodothyronine deiodinase

Indexed keywords

IODIDE PEROXIDASE; IODOTHYRONINE DEIODINASE 2; LIOTHYRONINE; THYROID HORMONE; THYROXINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOIMMUNE THYROIDITIS; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID HORMONE BLOOD LEVEL; THYROXINE BLOOD LEVEL;

ADULT; ALGORITHMS; AUTOIMMUNITY; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; IODIDE PEROXIDASE; ITALY; MIDDLE AGED; MOUTH MUCOSA; POLYMORPHISM, SINGLE NUCLEOTIDE; THYROID GLAND; THYROID HORMONES; THYROIDITIS, AUTOIMMUNE;

EID: 84879026134     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8618     Document Type: Article

References (19)

1. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest 2006, 116: 2571-9. (Pubitemid 44511617)
2. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 2002, 23: 38-89. (Pubitemid 34185306)
3. Baqui M, Botero D, Gereben B, et al. Human type 3 iodothyronine selenodeiodinase is located in the plasma membrane and undergoes rapid internalization to endosomes. J Biol Chem 2003, 278: 1206-11. (Pubitemid 36790803)
4. Canani LH, Capp C, Dora JM, et al. The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2005, 90: 3472-8. (Pubitemid 41014316)
5. Mentuccia D, Proietti-Pannunzi L, Tanner K, et al. Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the beta-3-adrenergic receptor. Diabetes 2002, 51: 880-3. (Pubitemid 34760206)
6. Heemstra KA, Hoftijzer H, van der Deure WM, et al. The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turnover and decreased femoral neck bone mineral density. J Bone Miner Res 2010, 25: 1385-91.
7. Grarup N, AndersenMK, Andreasen CH, et al. Studies of the common DIO2 Thr92Ala polymorphism and metabolic phenotypes in 7342 Danish white subjects. J Clin Endocrinol Metab 2007, 92: 363-6. (Pubitemid 46067554)
8. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab 2009, 94: 1623-9.
9. De Vito P, Incerpi S, Pedersen JZ, Luly P, Davis FB, Davis PJ. Thyroid hormones as modulators of immune activities at the cellular level. Thyroid 2012, 21: 879-90.
10. Barreiro Arcos ML, Sterle HA, Paulazo MA, et al. Cooperative nongenomic and genomic actions on thyroid hormone mediated-modulation of T cell proliferation involve up-regulation of thyroid hormone receptor and inducible nitric oxide synthase expression. J Cell Physiol 2011, 226: 3208-18.
11. Klecha AJ, Genaro AM, Lysionek AE, Caro RA, Coluccia AG, Cremaschi GA. Experimental evidence pointing to the bidirectional interaction between the immune system and the thyroid axis. Int J Immunopharmacol 2000, 22: 491-500. (Pubitemid 30214122)
12. Marino F, Guasti L, Cosentino M, et al. Thyroid hormone regulation of cell migration and oxidative metabolism in polymorphonuclear leukocytes: clinical evidence in thyroidectomized subjects on thyroxine replacement therapy. Life Sci 2006, 78: 1071-7. (Pubitemid 43143464)
13. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological well-being in patients on 'adequate' doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf) 2002, 57: 577-85. (Pubitemid 35316973)
14. Walsh JP. Dissatisfaction with thyroxine therapy - could the patients be right? Curr Opin Pharmacol 2002, 2: 717-22. (Pubitemid 35476925)
15. Bunevicius R, Prange AJ. Mental improvement after replacement therapy with thyroxine plus triiodothyronine: relationship to cause of hypothyroidism. Int J Neuropsychopharmacol 2000, 3: 167-74. (Pubitemid 30429360)
16. Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ Jr. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 1999, 340: 424-9. (Pubitemid 29084773)
17. Siegmund W, Spieker K, Weike AI, et al. Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14 : 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clin Endocrinol (Oxf) 2004, 60: 750-7. (Pubitemid 38788084)
18. Slawik M, Klawitter B, Meiser E, et al. Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine. J Clin Endocrinol Metab 2007, 92: 4115-22. (Pubitemid 350074720)
19. Escobar-Morreale HF, Botella-Carretero JI, Gomez-Bueno M, Galan JM, Barrios V, Sancho J. Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med 2005, 142: 412-24.